Cecilia Garlanda: Curriculum vitae Cecilia Garlanda

Cecilia Garlanda: Curriculum vitae
Cecilia Garlanda graduated in Veterinary Medicine at the Università degli Studi di Milano, in 1990.
She worked at the Institute of Pharmacological Research "Mario Negri" in the Laboratory of
Immunology, from 1990 to 2005, and in the Département de Biologie Moléculaire et StructuraleUnité INSERM 217-Centre d'Etudes Nucléaires de Grenoble, France, in 1994-1995. From 2005, she
is the head of the Laboratory of Experimental Immunopathology at the Istituto Clinico Humanitas.
She contributed to characterize murine models of vascular tumours, to produce monoclonal
antibodies against the murine vascular endothelium, to generate and phenotypically characterize
gene-modified mice. She has worked on innate immunity and on the regulation of inflammatory
responses. Her activity has been focused on the functional characterization of original molecules
of the immune system, in particular on the characterization of the biological activity of the long
pentraxin PTX3 in the context of innate immune responses to pathogens of fungal, bacterial or
viral origin, and in the regulation of inflammatory responses in conditions of infections or tissue
damage, such as cardiovascular disorders, wound healing and cancer. She contributed to
characterize the diagnostic potential of PTX3 in human inflammatory diseases and is now involved
in the translation of PTX3 to the clinic as therapeutic tool in infectious diseases. She is also focused
on TIR8/SIGIRR, a member of the family of IL-1 Receptors and Toll Like Receptors, acting as a
negative regulator of inflammatory and immune responses triggered by TLR engagement and by
IL-1 family members, in particular in the context of inflammatory diseases, infections and cancer.
The activities of her Laboratory mainly consist in pre-clinical studies, which take advantage of
gene-modified animals generated by her group, and are finalized to the possibility of translating
these molecules to the clinic, as potential diagnostic and/or therapeutic tools.
She has worked as collaborator or principal investigator in EU and national projects (FP7 MUGEN,
FP6 EMBIC, Cariplo, Fondazione per la Ricerca sulla Fibrosi Cistica, Ministero della Salute - Ricerca
Finalizzata e Alleanza contro il Cancro, Telethon) focused on inflammation in different contexts,
cancer and infectious diseases.
She is author of 134 scientific publications on international journals, 15 chapters on scientific
books, several abstracts at congresses and of a patent.
She is Reviewer ad hoc for the following journals: Blood, European J. Immunology, J. Leukocyte
Biology, Microbes Infections, Arteriosclerosis Thrombosis and Vascular Biology, Cancer Research,
Clinical Chemistry and Laboratory Medicine Faseb J., Intensive Care Medicine, J. Reumathology,
International J. Vascular Medicine, J Cell Biochemistry, Leukemia Research, Placenta, PLOSone,
Frontiers in Immunology.
Total number of publications on peer-reviewed journals: 134
List of selected publications
1- Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B,
Peri G, Doni A, Vago L, Botto M, De Santis R, Carminati P, Siracusa G, Altruda F, Vecchi A, Romani L,
Mantovani A. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune
response. Nature 2002; 420: 182-186
2- Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, Muzio M, Bergottini R,
Scanziani E, Vecchi A, Hirsch A, Mantovani A. Intestinal inflammation in mice deficient in Tir8, an
inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004; 101: 3522-3526
3- Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate
immunity, inflammation, matrix deposition, and female fertility. Ann. Rev. Immunol. 2005, 23:
337-366.
4- Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, Sironi M, Nebuloni M, Zorini
EO, Scanziani E, Mantovani A. Increased susceptibility to colitis-associated cancer of mice lacking
TIR8,
an
inhibitory
member
of
the
interleukin-1
receptor
family.
Cancer Res. 2007 Jul 1;67(13):6017-21.
5- Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda
C, Mantovani A.Cardioprotective function of the long pentraxin PTX3 in acute myocardial
infarction. Circulation. 2008 Feb 26;117(8):1055-64.
6- Garlanda C., Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory
functions on inflammation and T cell polarization. Trends in Immunology 2009 Sep;30(9):439-46.
7- Norata GD, Garlanda C, Catapano AL. The Long Pentraxin PTX3: A Modulator of the
Immunoinflammatory Response in Atherosclerosis and Cardiovascular Diseases.
Trends
Cardiovasc Med. 2010 Feb;20(2):3 5-40.
8- Bottazzi B, Doni A, Garlanda C, Mantovani A. An Integrated View of Humoral Innate Immunity:
Pentraxins as a Paradigm. Annu Rev Immunol. 2010 Apr 23;28:157-83.
9- Moalli F., Doni A., Deban L., Zelante T., Zagarella S., Bottazzi B., Romani L, Mantovani A., and
Garlanda C. Role of complement and Fcγ receptors in the protective activity of the long pentraxin
PTX3 against Aspergillus fumigatus. Blood. 2010 Dec 9;116(24):5170-80.
10- Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity.
2013 Dec 12;39(6):1003-18.
11- Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Riva F, Barbati E, Nebuloni M, Cvetko
Krajinovic L, Markotic A, Valentino S, Doni A, Tartari S, Graziani G, Montanelli A, Delneste Y,
Svanborg C, Garlanda C, Mantovani A. The humoral pattern recognition molecule PTX3 is a key
component of innate immunity against urinary tract infection. Immunity. 2014 Apr 17;40(4):62132.

Download Report